Rinri Therapeutics is a pioneering therapeutic discovery and development company specializing in regenerative cell therapy for hearing loss. Founded in 2018 by Professor Marcelo Rivolta at the University of Sheffield, the company is supported by Boehringer Ingelheim Venture Fund and UCB Ventures, BioCity, and The University of Sheffield. Rinri Therapeutics' flagship product is Rincell-1, a groundbreaking progenitor cell therapy that aims to regenerate auditory neurons and restore nerve signal transmission from the inner ear to the brain's auditory centers.

This innovative therapy shows great promise in reversing age-related hearing loss and Auditory Neuropathy. With an experienced management team, strong academic pedigree, and a focus on clinical development, Rinri Therapeutics is at the forefront of revolutionizing the treatment of sensorineural hearing loss. They are dedicated to addressing the unmet clinical needs of individuals living with hearing loss and their families by bringing their cutting-edge cell therapy from the laboratory to the patients who need it most